RESUMEN
The aim of this study was to characterize the involvement of long noncoding RNA HOTAIR in gastric cancer development. Measurement of HOTAIR and miRNA-206 expression by in situ hybridization (ISH) and analyzed for the correlation between HOTAIR and miRNA-206 in gastric cancer tissues. To evaluate the effects of HOTAIR in gastric cancer, MTT assay, flow cytometry, transwell, and wound healing assays were applied. To explain the mechanism behind HOTAIR's involvement, the expression of proteins related to it was also measured by Western blotting. Finally, correlations among related factors were determined by a luciferase target experiment. HOTAIR expression significantly increased, and miRNA-206 expression significantly decreased in cancer tissues (p < .01 and p < .001, respectively); HOTAIR knockdown suppressed cell viability, increased cell apoptosis by maintaining cells in the G1 phase, and inhibited cell invasion and migration by regulating miRNA-206 expression (p < .01 or p < .001). Meanwhile, with HOTAIR knockdown, CCND1 and CCND2 protein expressions were significantly suppressed, whereas miRNA-206 expression increased (p < .01 or p < .001). HOTAIR was shown to target miRNA-206 and miRNA-206 targeted CCND1 and CCND2. HOTAIR knockdown had antitumor effects by suppressing CCND1 and CCND2 expression by stimulating miRNA-206 in gastric cancer in vitro study.
RESUMEN
Portal hypertensive gastropathy (PHG) is a disease caused by cirrhotic (or non-cirrhotic) portal hypertension, with a typical feature of snake-skin appearance of the gastric mucosa under endoscope. Many studies have shown that portal hypertension is a necessary condition for the development and progression of PHG. PHG is often complicated by acute or chronic upper gastrointestinal bleeding, which may be the direct reason for patients to visit the hospital. Therefore, the study of the diagnosis and treatment of PHG is very important in clinical practice. This article reviews the research advances in the pathogenesis, classification, diagnosis, and treatment of PHG.
RESUMEN
The cell-free plasma DNA (cfpDNA) has been suggested as a useful tumor marker for its quantitative and qualitative tumor-specific alterations that reflect the biological characteristics and the progression and outcomes of tumors.Therefore,it has been used as liquid biopsy to detect cfpDNA in peripheral blood for the diagnosis,monitoring of clinical effects,and prognosis of malignancies
RESUMEN
Objective To investigate the diagnosis and treatment of mutinous cystadenoma of the pancreas.Method The clinical data of 12 cases with pancreatic mutinous cystadenoma was confirmed by pathology from May 2000 to May 2009 was retrospectively analysed.Results The accuracy rates of ultrasound,CT and MRCP were 50.0%(5/10),66.7%(6/9)and 83.3%(5/6)respectively.Pancreaticoduodenectomy,duodenum-preserving pancreatic head resection,distal pancreatic resection,distal pancreaticresection and splenectomy,segment pancreatic resection were performed according to the site of tumors.Completed resectable rate was 91.7%(11/12),palliative resection in 1 case,postoperative pancreatic leakage in 3 cases.2 cases cured;1 case died of intra-abdominal infection caused by pancake fistula 1 month later;1 case died of tumor recurrence and metastasis 25 months later.Conclusions Pancreatic cystic neoplasms is lack of specific clinical manifestations.Combined with application of imaging methods,can improve the diagnosis rate.Operation is the most effective therapy.The feasible procedures for mucinous cystadenoma of the pancmas should be choiced according to the site of tumors.
RESUMEN
Objective To investigate the safety and feasibility of pancreatoduodenostomy com-bined with resection of PV/SMV for carcinoma of the head of pancreas.Methods The clinical data of 12 cases of carcinoma of the haed of pancreas underwent pancreatoduodenostomy in combination with resection of PV/SMV were retrospectively analyzed.Their data were compared with those of 40 cases of carcinoma of the haed of pancreas underoing pancreatoduodenostomy in the same period of time.Results Of the 12 cases, 3 underwent PV resection and reconstruction with ePTEE grafts, 3 PV re-section and reconstruction with end-end anastomosis, 6 PV lateral wall partial resection and recon-struction.There were no significantly differences in age, sex, time of operation, operative bleeding, complication, mortality rate, site of tumor,t umor differentiation, lymphtie metastasis, margin posi-tive resection and survival between the two groups.Conclusion Pancreatoduodenostomy combined with resection of PV/SMV is safe for carcinoma of the head of pancreas.
RESUMEN
Objective To summarize the experience in performance of hepatopancreatoduodenostomy for hilar cholangiocarcinoma. Methods The clinical data of 11 cases of hilar cholangiocarcinoma receiving hepatopancreatoduodenostomy in our hospital from June 2000 to January 2008 were retrospectively analyzed. Results For Bismush-corlitte classification, 8 cases were grade Ⅲ the others Ⅳ.Quadrate lobectomy plus pancreaticoduodenectomy was performed in 2 patients, caudate lobectomy plus pancreaticoduodenostomy in 5, hepatectomy in right half plus caudate lobectomy, pancreaticoduodenostomy and PV lateral wall partial resection and reconstruction in 1, hepatectomy in left half and pancreaticoduodenostomy in 3. There were no death. Three patients had the complication of biliary fistula,1 pancreatic fistula, 2 pulmonary infection and 1 liver functional failure. The follow-up in 8 patients showed that the longest survival was 63 months. Conclusion HPD is safe and feasible for treatment of hilar cholangiocarcinoma invading the region of pancreaticoduodensum and it can promote the life quality of patients.
RESUMEN
Objective To analyze the effect of inner diameter of pancreatic duct following pancreaticoduodenectomy on pancreatic fistula.Methods From January 1995 to December 2008,256 patients underwent pancreaticoduodenectomy were divided into four groups based on the types of pancreaticojejunostomy: end-to-side "mucosa-to-mucosa" anastomosis group(n=115),end-to-end "mucosa-to-mucosa" anastomosis group(n=71),end-to-end invaginated pancreaticojejunostomy group(n=43) and pancreaticogastrostomy group(n=27).Alternatively,238 patients were divided into two groups according to drainage ways: stenting tube for internal drainage group(n=132) and stenting tube for external drainage group(n=106).Furthermore,233 cases were divided into three groups on the basis of inner diameter of pancreatic duct: ≤0.2 cm group(n=54),0.2-0.4 cm group(n=93) and ≥0.4 cm group(n=76).Then,the incidence rate of pancreatic fistula of each group was compared.Results The incidence of pancreatic fistula was 8.20%(21/256).The incidence of pancreatic fistula for different types of pancreaticojejunostomy was as follow: end-to-side "mucosa-to-mucosa" anastomosis group(7.83%,9/115),end-to-end "mucosa-to-mucosa" anastomosis group(7.04%,5/71),end-to-end pancreaticogastrostomy invaginated group(13.95%,6/43) and pancreaticogastrostomy group(3.70%,1/27),in which there wasn't significant difference in 4 groups(?2=2.763,P=0.430).There was no significant difference of the incidence of pancreatic fistula between stenting tube for internal drainage group(9.10%,12/132) and stenting tube for external drainage group(8.49%,9/106),?2=0.126,P=0.722.The incidence of pancreatic fistula in ≥0.4 cm group,0.2-0.4 cm group and ≤0.2 cm group was respectively 0,15.05%(14/93) and 11.11%(6/54),and the difference was significant(?2=12.009,P=0.002).No correlation was found between the incidence of pancreatic fistula of different inner diameter of pancreatic duct and the types of pancreaticojejunostomy (?2=1.878,P=0.598).Conclusion The inner diameter of pancreatic duct is an important factor for postoperative pancreatic fistula. No relationship is found between the types of pancreaticojejunostomy and pancreatic fistula in this study.